ADVERTISEMENTs

Diku Mandavia joins DeepSight Technology as CMO

With 26 years of medical expertise, Mandavia will lead the company's clinical and commercial operations, advancing innovative ultrasound solutions to improve diagnostic accuracy and patient outcomes.

Dr. Diku Mandavia, CMO, DeepSight Technology / LinkedIn

DeepSight Technology, a pioneer in medical device innovation headquartered in California, has announced the appointment of Dr. Diku Mandavia as its new Chief Medical Officer (CMO).

In this strategic role, Mandavia will oversee the medical direction of the company’s clinical and commercial operations, playing a crucial role in advancing DeepSight's innovative ultrasound solutions, including the NeedleVue Ultrasound System, OnPoint Imaging, and EchoLux Ultrasound System.

Mandavia shared his excitement on LinkedIn, stating, “I am excited to join the team at DeepSight Technology to deliver breakthrough imaging and precision needle guidance to clinicians around the world.”

Mandavia brings 26 years of medical expertise and leadership to DeepSight, with a strong background in medical imaging and precision needle guidance. 

His appointment marks a significant milestone for the company as it continues to revolutionize the healthcare landscape with cutting-edge technologies that enhance diagnostic accuracy and improve patient outcomes.

Nader Sadrzadeh, founder, and CEO of DeepSight Technology, expressed his enthusiasm for the appointment, stating, "We are thrilled to welcome Dr. Diku Mandavia to DeepSight as our new Chief Medical Officer. His exceptional leadership and medical expertise will be instrumental in driving our mission to deliver groundbreaking medical imaging solutions. We are confident that his vision and experience will propel us toward new heights of innovation."

With his extensive experience in the medical field, Mandavia is poised to lead DeepSight’s efforts to provide clinicians with the tools they need to achieve greater precision in medical imaging, ultimately improving patient care globally.

Comments